-IBIS-1.5.0-
tx
reproductive system
prostate cancer
nutrition

dietary guidelines

eating principles:
• alkaline fasts under supervision of physician (see Fasting in materia medica)

therapeutic foods:
• pumpkin seeds (raw) dosage: 25 four times per day
• anise, tangerine, cherries, figs, lychee, sunflower seeds, mangoes, seaweeds (Ni, p. 153)
• foods rich in Zinc and Vitamin E; squash seeds, almonds, sesame seeds, tahini, kelp (Jensen, p. 61)

fresh juices:
• carrot (Walker, p. 151)
• carrot and spinach (Walker)
• carrot, beet, and cucumber (Walker, p. 151)
• carrot, asparagus, and lettuce (Walker, p. 151)
• lemon juice in warm water (Walker, p. 151)

recommendations for all cancers:
• seaweeds, mushrooms (Chinese black, Shiitake), figs, beets, beet tops, papaya, mung beans, licorice, sea cucumbers, carrot, garlic, walnut, lychee fruit, mulberries, asparagus, pumpkin, burdock, dandelion greens, white fungus, taro roots, pearl barley, grains, fresh fruits and vegetables (Ni, pp. 108-109)

specific remedies:
• soup of black or ling zhi mushrooms and white fungus, three times daily (Ni, pp. 108-109)
• boil together mung beans, pearl barley, adzuki beans, and figs (Ni, pp. 108-109)
• dandelion, burdock and chrysanthemum flower tea (Ni, pp. 108-109)

avoid:
• dairy products, rich foods, fatty foods, greasy foods, stimulating foods, coffee, caffeine, alcohol (Ni, p. 153)
• meat, chicken, cinnamon, anise, pepper, spicy foods, smoking, constipation, stress


supplements

• Vitamin A (Whelen, 1983)
• Selenium:
One study involving 974 men, with a history of skin cancer, who took 200 mcg daily (in the form of selenium-rich yeast tablets) for 4-5 years found a 63% reduction in their risk of prostate cancer for 6.5 years after they stopped the supplementation. (Clark LC, et al. Br J Urol 1998 May;81(5):730-734.)

• Zinc (Habib, 1976)
• Shark cartilage 2 g per kg body wt q d (Lane, 1992)
• Vitamins C and E for patients using adriamycin: antioxidants, specifically reduces cardiac toxicity of adriamycin (Doxorubicin) (Fujita, et al., 1982, 42: p. 309-316; Ellison, 1985; 37 (3): 112-113; Am Heart J, 1986; 111: p. 95)

drug interactions:
» Vitamins B1, B2, B3, Vitamin K and folic acid can become deficient in patients using chemotherapy due to consequent anorexia, damage to the digestive tract, and malabsorption (Dreizen, et al., 1990; 87 (1): 163-170)
» Vitamin K has been found to potentiate various chemotherapeutic drugs in animals (Taper, et al., 1987; 40: 575-579)
» Vitamin A and cancer chemotherapy, esp. fluorouracil (5-FU): vitamin A enhances antitumor effect in animals (Nakagawa, et al., 1985; 76: 887-894)


footnotes

Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998 May;81(5):730-734.
Abstract: OBJECTIVE: To test if supplemental dietary selenium is associated with changes in the incidence of prostate cancer. PATIENTS AND METHOD: A total of 974 men with a history of either a basal cell or squamous cell carcinoma were randomized to either a daily supplement of 200 microg of selenium or a placebo. Patients were treated for a mean of 4.5 years and followed for a mean of 6.5 years. RESULTS: Selenium treatment was associated with a significant (63%) reduction in the secondary endpoint of prostate cancer incidence during 1983-93. There were 13 prostate cancer cases in the selenium-treated group and 35 cases in the placebo group (relative risk, RR=0.37, P=0.002). Restricting the analysis to the 843 patients with initially normal levels of prostate-specific antigen (< or = 4 ng/mL), only four cases were diagnosed in the selenium-treated group and 16 cases were diagnosed in the placebo group after a 2 year treatment lag, (RR=0.26 P=0.009). There were significant health benefits also for the other secondary endpoints of total cancer mortality, and the incidence of total, lung and colorectal cancer. There was no significant change in incidence for the primary endpoints of basal and squamous cell carcinoma of the skin. In light of these results, the 'blinded' phase of this trial was stopped early. CONCLUSIONS: Although selenium shows no protective effects against the primary endpoint of squamous and basal cell carcinomas of the skin, the selenium-treated group had substantial reductions in the incidence of prostate cancer, and total cancer incidence and mortality that demand further evaluation in well-controlled prevention trials.